A Phase III, Multi-centre, Randomized Study to Compare the Efficacy and Safety of Levonadifloxacin (IV and Oral) With Linezolid (IV and Oral) in Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
Latest Information Update: 30 Jun 2020
At a glance
- Drugs Alalevonadifloxacin (Primary) ; Levonadifloxacin (Primary) ; Linezolid; Linezolid
- Indications Bacterial infections; Skin infections
- Focus Registrational; Therapeutic Use
- Sponsors Wockhardt
- 16 Jan 2020 According to a Wockhart media release, DCGI has approved Wockhardt 2 new antibiotics, EMROK (IV) and EMROK O (Oral), for acute bacterial skin and skin structure Infections including diabetic foot infections and concurrent bacteraemia based on the Phase 3 study involving 500 patients in 40 centres across India.
- 02 Aug 2019 Status changed from active, no longer recruiting to completed.
- 12 Nov 2018 Status changed from recruiting to active, no longer recruiting.